Table 3.
A summary of recent ongoing clinical trials on TLR agonists started after 2019.
| Target TLR | TLR agonist | Companion treatment | Conditions∗ | Phase | Status | NCT number |
|---|---|---|---|---|---|---|
| TLR2/4 | BCG, PPD, Typhim Vi | Chemotherapy, radiofrequency ablation | Colorectal cancer | I | Not yet recruiting | NCT04062721 |
| TLR3 | Poly-ICLC | Peptide vaccine, anti-CD40 | Melanoma | I/II | Recruiting | NCT04364230 |
| Rintatolimod | Anti-PD-1, chemotherapy | Ovarian cancer recurrent | I/II | Recruiting | NCT03734692 | |
| TLR4 | GLA-SE | N/A | Lymphoma, T cell, cutaneous | II | Withdrawn | NCT03742804 |
| Anti-CTLA-4, anti-PD-1, chemotherapy | Colorectal cancer metastatic | I | Withdrawn | NCT03982121 | ||
| TLR7 | BNT411 | Anti-PDL-1, chemotherapy | Solid tumor, lung cancer | I/II | Recruiting | NCT04101357 |
| Imiquimod | Anti-PD-1, focused ultrasound ablation | Multiple solid tumors | I | Recruiting | NCT04116320 | |
| RO7119929 | Anti-IL-6 receptor | Biliary tract and liver cancer | I | Recruiting | NCT04338685 | |
| SHR2150 | Chemotherapy, anti-PD-1, anti-CD47 | Solid tumor | I/II | Recruiting | NCT04588324 | |
| TLR7/8 | TransCon | Anti-PD-1 | Solid tumors | I/II | Recruiting | NCT04799054 |
| TLR8 | Motolimod | Anti-PD-1 | Carcinoma, squamous cell | I | Recruiting | NCT03906526 |
| TLR9 | CMP-001 | Anti-OX40 | Pancreatic cancer, unresectable solid neoplasm | I/II | Not yet recruiting | NCT04387071 |
| Anti-PD-1 | Melanoma | II | Recruiting | NCT04708418 | ||
| NCT04401995 | ||||||
| SD-101 | Radiation therapy, anti-PD-1 | Pancreatic cancer | I | Recruiting | NCT04050085 | |
| Anti-OX40 | Malignant solid neoplasm | I | Recruiting | NCT03831295 | ||
| Tilsotolimod | Anti-CTLA-4, anti-PD-1 | Advanced cancer | I | Recruiting | NCT04270864 |
∗Indicated conditions are summarized in this table. Complete information is available via the provided ClinicalTrials.gov identifier (NCT number).